Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
10.05
+0.35 (3.61%)
Mar 28, 2025, 4:00 PM EDT - Market closed

Company Description

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders.

Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders.

Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Rapport Therapeutics, Inc.
Rapport Therapeutics logo
Country United States
Founded 2022
IPO Date Jun 7, 2024
Industry Biotechnology
Sector Healthcare
Employees 69
CEO Abraham Ceesay

Contact Details

Address:
1325 Boylston Street, Suite 401
Boston, Massachusetts 02215
United States
Phone 857 321 8020
Website rapportrx.com

Stock Details

Ticker Symbol RAPP
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0002012593
CUSIP Number 75383L102
ISIN Number US75383L1026
Employer ID 88-0724208
SIC Code 2834

Key Executives

Name Position
Abraham N. Ceesay M.B.A. Chief Executive Officer, President, Treasurer and Director
Dr. Steven M. Paul M.D. Founder and Independent Chairman
Dr. Troy A. Ignelzi Chief Financial Officer
Cheryl Gault Chief Operating Officer
David Bredt M.D., Ph.D. Founder and Chief Scientific Officer
Karina Chmielewski Chief Information Officer and Head of Operations
Julie DiCarlo Head of Communications and Investor Relations
Kathleen A. Wilkinson Chief People Officer
Swamy Yeleswaram Ph.D. Chief Development Officer
Dr. Arnold R. Gammaitoni Pharm.D. Senior Vice President of Medical Affairs

Latest SEC Filings

Date Type Title
Mar 14, 2025 144 Filing
Mar 11, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 11, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report
Mar 3, 2025 8-K Current Report
Feb 13, 2025 SCHEDULE 13G Filing
Jan 10, 2025 8-K Current Report
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals